Skip to main
TVTX
TVTX logo

Travere Therapeutics (TVTX) Stock Forecast & Price Target

Travere Therapeutics (TVTX) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 46%
Buy 38%
Hold 15%
Sell 0%
Strong Sell 0%

Bulls say

Travere Therapeutics has demonstrated strong commercial execution in promoting FILSPARI, particularly with the recent removal of previous Risk Evaluation and Mitigation Strategy (REMS) requirements, which is expected to enhance prescriber willingness to adopt the therapy. This removal alleviates logistical burdens for both patients and healthcare providers, thereby boosting the potential market for this treatment. Furthermore, the positive market reaction following the cancellation of an Advisory Committee meeting, in conjunction with these regulatory easing measures, suggests an optimistic outlook for the company's stock performance moving forward.

Bears say

The financial outlook for Travere Therapeutics is negatively impacted by the potential for failed or inconclusive clinical trials, which can significantly hinder the progression of its lead product candidate, sparsentan, through the development pipeline. Moreover, the company's ability to secure adequate funding remains a critical concern, particularly in an environment characterized by mixed sentiment surrounding regulatory decisions and increased scrutiny following recent FDA actions. Additionally, the volatility stemming from leadership changes and shifting review practices adds to investor uncertainty, further diminishing confidence in the company's future prospects.

Travere Therapeutics (TVTX) has been analyzed by 13 analysts, with a consensus rating of Buy. 46% of analysts recommend a Strong Buy, 38% recommend Buy, 15% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Travere Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Travere Therapeutics (TVTX) Forecast

Analysts have given Travere Therapeutics (TVTX) a Buy based on their latest research and market trends.

According to 13 analysts, Travere Therapeutics (TVTX) has a Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $37.77, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $37.77, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Travere Therapeutics (TVTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.